Anemia, Renal Dysfunction, and Their Interaction in Patients With Chronic Heart Failure

American Journal of Cardiology

Volumn 98, Issue 3, 2006, Pages 391-398

  de Silva, Ramesh ^a   Rigby, Alan S ^a   Witte, Klaus K A ^a   Nikitin, Nikolay P ^a   Tin, Lwin ^a   Goode, Kevin ^a   Bhandari, Sunil ^b   Clark, Andrew L ^a   Cleland, John G F ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b HULL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN;

ADULT; AGED; ANEMIA; ARTICLE; CALCULATION; CARDIAC PATIENT; COMMUNITY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GLOMERULUS FILTRATION RATE; HEALTH PROGRAM; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEMOGLOBIN DETERMINATION; HUMAN; IRON DEFICIENCY ANEMIA; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; OUTCOME ASSESSMENT; OUTPATIENT; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS;

AGED; ANEMIA; CHRONIC DISEASE; DISEASE PROGRESSION; FEMALE; FERRITINS; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEART FAILURE, CONGESTIVE; HEMOGLOBINS; HUMANS; MALE; MYOCARDIAL CONTRACTION; PREVALENCE; PROGNOSIS; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 33745961565     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.01.107     Document Type: Article

References (30)

1. Khand A., Gemmel I., Clark A.L., and Cleland J.G. Is the prognosis of HF improving?. J Am Coll Cardiol 36 (2000) 2284-2286
2. Hillege H.L., Girbes A.R., de Kam P.J., Boomsma F., de Zeeuw D., Charlesworth A., Hampton J.R., and van Veldhuisen D.J. Renal function, neurohormonal activation, and survival in patients with chronic HF. Circulation 102 (2000) 203-210
3. Ezekowitz J.A., McAlister F.A., and Armstrong P.W. Anemia is common in HF and is associated with poor outcomes. insights from a cohort of 12 065 patients with new-onset HF. Circulation 107 (2003) 223-225
4. Horwich T.B., Fonarow G.C., Hamilton M.A., MacLellan W.R., and Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced HF. J Am Coll Cardiol 39 (2002) 1780-1786
5. Silverberg D., Wexler D., Blum M., Wollman Y., and Iaina A. The cardio-renal anemia syndrome. does it exist?. Nephrol Dial Transplant 18 suppl (2003) 7-12
6. Al-Ahmad A., Rand W.M., Manjunath G., Konstam M.A., Salem D.N., Levey A.S., and Sarnak M.J. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38 (2001) 955-962
7. McClellan W.M., Flanders W.D., Langston R.D., Jurkovitz C., and Presley R. Anemia and renal insufficiency are independent risk factors for death among patients with congestive HF admitted to community hospitals. a population-based study. J Am Soc Nephrol 13 (2002) 1928-1936
8. Hunt S.A., Baker D.W., Chin M.H., Cinquegrani M.P., Feldman A.M., Francis G.S., Ganiats T.G., Goldstein S., Gregoratos G., Jessup M.L., et al. ACC/AHA guidelines for the evaluation and management of chronic HF in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of HF). J Am Coll Cardiol 38 (2001) 2101-2113
9. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D., and Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine. a new prediction equation. Ann Intern Med 130 (1999) 461-470
10. Dries D.L., Exner D.V., Domanski M.J., Greenberg B., and Stevenson L.W. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 35 (2000) 681-689
11. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease. evaluation, classification, and stratification. Am J Kidney Dis 39 (2002) 266-269
12. Rigby A.S. Statistical methods in epidemiology. II. The odds ratio as an approximation to the relative risk. Disabil Rehabil 21 (1999) 145-151
13. Altman D.G., Machin D., Bryant D., and Gardner M.J. Statistics With Confidence. 2nd Ed. (2000), BMJ, London
14. Perneger T.V. What's wrong with Bonferonni adjustments?. BMJ 316 (1998) 1236-1238
15. Ottman R. Gene-environment interaction. definitions and study designs. Prevent Med 25 (1996) 764-770
16. Botto L.D., and Khoury M.J. Commentary: facing the challenge of gene-environment interaction: the two-by-four table and beyond. Am J Epidemiol 153 (2001) 1016-1020
17. Rothman K.J. Synergy and antagonism in cause-effect relationships. Am J Epidemiol 99 (1974) 385-388
18. Rothman K.J. The estimation of synergy or antagonism. Am J Epidemiol 103 (1976) 506-511
19. Felker G.M., Gattis W.A., Leimberger J.D., Adams K.F., Cuffe M.S., Gheorghiade M., and O'Connor C.M. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated HF. Am J Cardiol 92 (2003) 625-628
20. Cromie N., Lee C., and Struthers A.D. Anemia in chronic HF. what is its frequency in the UK and its underlying causes?. Heart 87 (2002) 377-378
21. Witte K.K., de Silva R., Chattopadhyay S., Ghosh J., Cleland J.G., and Clark A.L. Are hematinic deficiencies the cause of anemia in chronic HF?. Am Heart J 147 (2004) 924-930
22. Goch J., Birgegard G., Danielson B.G., and Wikstrom B. Iron absorption in patients with chronic uremia on maintenance hemodialysis and in healthy volunteers measured with a simple oral iron load test. Nephron 73 (1996) 403-406
23. Bhandari S., Norfolk D., Brownjohn A., and Turney J. Evaluation of red blood cell ferritin and reticulocyte measurements in monitoring response to intravenous iron therapy. Am J Kidney Dis 30 (1997) 814-821
24. van der Meer P., Voors A.A., Lipsic E., van Gilst W.H., and van Veldhuisen D.J. Erythropoietin in cardiovascular diseases. Eur Heart J 25 (2004) 285-291
25. Silverberg D.S., Wexler D., Blum M., Keren G., Sheps D., Leibovitch E., Brosh D., Laniado S., Schwartz D., Yachnin T., et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive HF improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35 (2000) 1737-1744
26. Mancini D.M., Katz S.D., Lang C.C., LaManca J., Hudaihed A., and Androne A.S. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic HF. Circulation 107 (2003) 294-299
27. Katz S.D., Mancini D., Androne A.S., and Hryniewicz K. Treatment of anemia in patients with chronic HF. J Card Fail 10 (2004) S13-S16
28. A study to assess the pharamcokinetics and pharmacodynamics of repeat-dose subcutaneous Darbopoetin Alfa in subjects with congestive HF and anemia, and a single dose in age- and sex-matched control subjects. Amgen Development, Europe 2001. Available at: http://www.amgen.com. Accessed June 5, 2006
29. Silverberg D.S., Wexler D., Sheps D., Blum M., Keren G., Baruch R., Schwartz D., Yachnin T., Steinbruch S., Shapira I., et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron. a randomized controlled study. J Am Coll Cardiol 37 (2001) 1775-1780
30. Silverberg D.S., Wexler D., Blum M., Tchebiner J.Z., Sheps D., Keren G., Schwartz D., Baruch R., Yachnin T., Shaked M., et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 18 (2003) 141-146